Figure 3

Imaging modalities delivery of RNAi therapeutics in cancer therapy and clinical applications

Loutfy H Madkour*

Published: 04 March, 2021 | Volume 5 - Issue 1 | Pages: 005-034

Schematic illustration of nanocarrier-mediated delivery of RNAi therapeutics: the biological barriers for gene silencing in cancer treatment include reaching the circulation, crossing the vascular barrier, cellular uptake, and endosomal escape. Following systemic administration in patients, the RNAi therapeutics could be transported to the blood vessels in tumor tissues. The gene vectors could escape from the sinusoidal and fenestrated capillaries and retain in the tumor regions. The gene vectors could be taken by cancer cells through endocytosis or ligand- mediated intracellular transport and then transferred into the cytoplasm to silence target genes for cancer therapy.

" alt="jro-aid1035-g003"class="img-responsive img-rounded " style="cursor:pointer">

Figure 3:

Schematic illustration of nanocarrier-mediated delivery of RNAi therapeutics: the biological barriers for gene silencing in cancer treatment include reaching the circulation, crossing the vascular barrier, cellular uptake, and endosomal escape. Following systemic administration in patients, the RNAi therapeutics could be transported to the blood vessels in tumor tissues. The gene vectors could escape from the sinusoidal and fenestrated capillaries and retain in the tumor regions. The gene vectors could be taken by cancer cells through endocytosis or ligand- mediated intracellular transport and then transferred into the cytoplasm to silence target genes for cancer therapy.

Read Full Article HTML DOI: 10.29328/journal.jro.1001035 Cite this Article Read Full Article PDF

More Images

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?